- Home
- PSQH vs TCRX Comparison
PSQH vs TCRX Comparison
Compare PSQH & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSQH
- TCRX
- Stock Information
- Founded
- PSQH 2021
- TCRX 2018
- Country
- PSQH United States
- TCRX United States
- Employees
- PSQH N/A
- TCRX N/A
- Industry
- PSQH Advertising
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PSQH Consumer Discretionary
- TCRX Health Care
- Exchange
- PSQH Nasdaq
- TCRX Nasdaq
- Market Cap
- PSQH 81.5M
- TCRX 90.5M
- IPO Year
- PSQH N/A
- TCRX 2021
- Fundamental
- Price
- PSQH $1.99
- TCRX $1.28
- Analyst Decision
- PSQH Strong Buy
- TCRX Strong Buy
- Analyst Count
- PSQH 2
- TCRX 7
- Target Price
- PSQH $6.00
- TCRX $9.86
- AVG Volume (30 Days)
- PSQH 778.5K
- TCRX 381.1K
- Earning Date
- PSQH 05-08-2025
- TCRX 05-06-2025
- Dividend Yield
- PSQH N/A
- TCRX N/A
- EPS Growth
- PSQH N/A
- TCRX N/A
- EPS
- PSQH N/A
- TCRX N/A
- Revenue
- PSQH $26,483,166.00
- TCRX $4,421,000.00
- Revenue This Year
- PSQH $85.69
- TCRX $68.86
- Revenue Next Year
- PSQH $62.08
- TCRX $62.06
- P/E Ratio
- PSQH N/A
- TCRX N/A
- Revenue Growth
- PSQH 201.84
- TCRX N/A
- 52 Week Low
- PSQH $1.63
- TCRX $1.02
- 52 Week High
- PSQH $7.77
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- PSQH 49.02
- TCRX 39.98
- Support Level
- PSQH $1.71
- TCRX $1.32
- Resistance Level
- PSQH $2.23
- TCRX $1.65
- Average True Range (ATR)
- PSQH 0.17
- TCRX 0.13
- MACD
- PSQH 0.05
- TCRX -0.02
- Stochastic Oscillator
- PSQH 47.86
- TCRX 12.24
About PSQH PSQ Holdings Inc.
PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.